Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.
| Revenue (TTM) | $17.76B |
| Gross Profit (TTM) | $8.24B |
| EBITDA | $2.20B |
| Operating Margin | 3.76% |
| Return on Equity | 8.61% |
| Return on Assets | 3.59% |
| Revenue/Share (TTM) | $18.52 |
| Book Value | $13.31 |
| Price-to-Book | 2.34 |
| Price-to-Sales (TTM) | 1.68 |
| EV/Revenue | 1.811 |
| EV/EBITDA | 11.42 |
| Quarterly Earnings Growth (YoY) | -85.40% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | $977.61M |
| Float | $976.99M |
| % Insiders | 0.02% |
| % Institutions | 5.39% |
Volatility is currently expanding
PHG launches HyperVue Integrated in the U.S., combining advanced coronary imaging and AI-driven physiology assessment to streamline cath lab workflows.
Koninklijke Philips NYSE: PHG reported third-quarter comparable sales growth of 3%, an 8% increase in equipment order intake and a 70-basis-point expansion in adjusted EBITA margin to 13%, as growth in Personal Health and Connected Care offset flat sales in Diagnosis & Treatment.
Koninklijke Philips N.V. (PHG) Q3 2026 Earnings Call Transcript
Philips (PHG) changes to a 'HOLD' and my stance is now more conservative after recent performance and valuation changes. PHG's operational and regulatory risks have not diminished; current risks center on China exposure, sleep segment recovery, and minor litigation. I cut my price target of $25.76/ADR, which means the upside is no longer there.
The Dutch health-technology company said it reached an agreement to resolve previous criminal and civil investigations related to product recalls in its respironics subsidiary.
Philips beats quarterly profit estimates driven by higher sales, gross margin
November 3, 2026 Q3 2026 Group performance Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment Group sales of EUR 4.4 billion, reflecting 3% comparable sales growth Income from operations of EUR 165 million Adjusted EBITA margin increased 70 basis points to 13.0%, with expansion across all business segments Operating cash flow of EUR 544 million; free cash flow of EUR 384 million Respironics reached agreement in principle with the US Department of Justice Philips reiterates its full-year 2026 outlook Roy Jakobs, CEO of Royal Philips: “We delivered an excellent 8% comparable order intake, led by broad-based order momentum in Diagnosis & Treatment, and 3% comparable sales growth in the third quarter, led by Personal Health and Connected Care. Our innovations and productivity measures drove continued margin expansion across all business segments.
New fixed, single-room configuration is designed to make DeepOCT+NIRS Imaging and X1-FFR physiology readily available for efficient cath lab workflows At TCT 2026, Philips will showcase its broader full picture portfolio, bringing together imaging, physiology and procedural guidance Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced U.S. commercial availability of the HyperVue Integrated System1, a new single room-based configuration of its HyperVue Imaging System for DeepOCT+NIRS imaging and X1-FFR physiology assessment. It is designed to keep advanced coronary imaging and physiology tools connected and readily available in the interventional suite.
October 29, 2026 New CE-marked solution leverages the industry-leading Philips Azurion platform to integrate CT-derived insights and treatment planning directly into the procedural workflow, helping physicians make informed decisions during treatment. Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and a pioneer in image-guided therapy, today announced the launch of Philips UniGuide 3D Live Guidance in Europe and other CE-marked markets.
Leading beauty industry voices, Dr. Aamna Adel, UK Consultant Dermatologist and HCP influencer , Alice Crossley, Principal Strategic Foresight Analyst at The Future Laboratory , and Tiffany Buathier, Founder of The New Well, share their perspectives on the next phase of beauty technology and what it means for the industry. AMSTERDAM, Oct. 27, 2026 /PRNewswire/ -- Personal care has become a meaningful part of daily well-being, with people making intentional choices about how they begin their mornings, unwind in the evening and care for themselves throughout the day.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PHG and any ticker you trade — then tracks every position and per-strategy win rate.
